What is the role of topiramate (Topamax) in the treatment of Lennox-Gastaut syndrome (LGS)?

Updated: Nov 09, 2018
  • Author: Koshi A Cherian, MD; Chief Editor: Amy Kao, MD  more...
  • Print

In a multicenter, double-blind, placebo-controlled trial, topiramate (Topamax) was found to be safe and effective as adjunctive therapy for patients with LGS. [20] The target dose was 6 mg/kg/d. In a long-term open-label extension portion of this trial (mean dosage 10 mg/kg/d), drop attacks were reduced by greater than half in 55% of patients, and 15% of patients were free of drop attacks for over 6 mo at the last visit. [19]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!